United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News FDA approval and $12m funding propel Femasys’ FemBloc toward market-ready milestone Discover how Femasys’ FemBloc advances with FDA clearance and $12 M in funding, propelling its non-surgical birth control toward commercialization. bySoujanya RaviNovember 3, 2025